Publications
ERN-Skin members are engaged to stimulate a collaborative clinical research in the field of rare skin diseases, in order to improve patient management. All following publications involve at least two reference centres from two different Member States within the ERN-Skin.
Legend

AIBD
Autoimmune Bullous Diseases
 European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II.
 European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I.
 S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV) S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)
 Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
 IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients
 International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid
 Paraneoplastic autoimmune multiorgan syndrome (PAMS) Paraneoplastic autoimmune multiorgan syndrome (PAMS)
 Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
 Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared
 Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic
 Pemphigus Pemphigus
 A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid
ALLOCATE
Acquired immunologicaL LOw prevalence and Complex AdulT diseases of thE SKIN
 Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data
 Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa
 External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort
 What causes hidradenitis suppurativa ?-15 years after What causes hidradenitis suppurativa ?-15 years after
 Metascoring Hidradenitis suppurativa Metascoring Hidradenitis suppurativa
 Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis
DNA
Cutaneous Diseases related to DNA repair Disorders and photosensitivity
EB
Inherited Epidermolysis Bullosa and skin fragility syndromes – Darier disease – Hailey-Hailey disease
 COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents
 QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study
 Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire
 Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
 Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts
 STAT3 targeting in dystrophic epidermolysis bullosa STAT3 targeting in dystrophic epidermolysis bullosa
- ERN-Skin clinical research update for Epidermolysis Bullosa (October 2020)
 Currently recruiting clinical therapy trials for Epidermolysis Bullosa (October 2020) Currently recruiting clinical therapy trials for Epidermolysis Bullosa (October 2020)
 EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
 Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients
 Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 “knock-out” Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 “knock-out”
 Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa
 Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa part 2 Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa part 2
 Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale
 Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
 Features of Epidermolysis Bullosa Simplex due to KLHL24 Mutations in 3 Italian Cases Features of Epidermolysis Bullosa Simplex due to KLHL24 Mutations in 3 Italian Cases
 Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa
 Epidermolysis bullosa simplex-generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype-phenotype correlation and in silico modeling analysis Epidermolysis bullosa simplex-generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype-phenotype correlation and in silico modeling analysis
 Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy Epidermolysis Bullosa Simplex with KLHL24 Mutations Is Associated with Dilated Cardiomyopathy
 Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network : Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network : Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease
ED
Ectodermal Dysplasias including Incontinentia Pigmenti and p63-associated disorders
IPPK
Ichthyosis and Palmoplantar Keratoderma
 Mutational Spectrum of the ABCA12 Gene and Genotype–Phenotype Correlation in a Cohort of 64 Patients with Autosomal Recessive Congenital Ichthyosis Mutational Spectrum of the ABCA12 Gene and Genotype–Phenotype Correlation in a Cohort of 64 Patients with Autosomal Recessive Congenital Ichthyosis
 Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma
 Hereditary palmoplantar keratoderma – phenotypes and mutations in 64 patients Hereditary palmoplantar keratoderma – phenotypes and mutations in 64 patients
 Meta-Analysis of Mutations in ALOX12B or ALOXE3 Identified in a Large Cohort of 224 Patients Meta-Analysis of Mutations in ALOX12B or ALOXE3 Identified in a Large Cohort of 224 Patients
 Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature
 Correction to: Italian translation, cultural adaptation, and pilot testing of a questionnaire to assess family burden in inherited ichthyoses Correction to: Italian translation, cultural adaptation, and pilot testing of a questionnaire to assess family burden in inherited ichthyoses
 Phenotypic Variability with SLURP1 Mutations and Diffuse Palmoplantar Keratoderma Phenotypic Variability with SLURP1 Mutations and Diffuse Palmoplantar Keratoderma
 Genetical, clinical, and functional analysis of a large international cohort of patients with autosomal recessive congenital ichthyosis due to mutations in NIPAL4 Genetical, clinical, and functional analysis of a large international cohort of patients with autosomal recessive congenital ichthyosis due to mutations in NIPAL4
 Burden of itch in ichthyosis: a multicentre study in 94 patients Burden of itch in ichthyosis: a multicentre study in 94 patients
 Italian translation, cultural adaptation, and pilot testing of a questionnaire to assess family burden in inherited ichthyoses Italian translation, cultural adaptation, and pilot testing of a questionnaire to assess family burden in inherited ichthyoses
 Alitretinoin in punctate palmoplantar keratoderma Alitretinoin in punctate palmoplantar keratoderma
 Alitretinoin reduces erythema in inherited ichthyosis Alitretinoin reduces erythema in inherited ichthyosis
 Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas – Diagnostic algorithm and principles of therapy Hereditary palmoplantar keratodermas. Part II: syndromic palmoplantar keratodermas – Diagnostic algorithm and principles of therapy
 Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features Hereditary palmoplantar keratodermas. Part I. Non-syndromic palmoplantar keratodermas: classification, clinical and genetic features
MCTD
Mendelian Connective Tissue Disorders
Mosaic
Cutaneous Mosaic Disorders : Naevi & Naevoid skin disorders – Complex vascular malformations and cutaneous and subcutaneous vascular tumors
 Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene
 Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research
 RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation
ToxiTEN
Severe Cutaneous Drug Reactions – Toxic Bullous Diseases
 Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus
 Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases
 Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus
 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group
